| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |